Alterity Therapeutics to Present at Bell Potter Healthcare Horizons Summit

lunes, 9 de marzo de 2026, 7:33 am ET1 min de lectura
ATHE--

Alterity Therapeutics will participate in the Bell Potter Healthcare Horizons Summit, with CEO David Stamler participating in a fireside chat and hosting 1-on-1 investor meetings. The company is focused on developing disease-modifying therapies for neurodegenerative diseases, including Multiple System Atrophy and Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and has demonstrated clinically meaningful efficacy in a Phase 2 clinical trial.

Alterity Therapeutics to Present at Bell Potter Healthcare Horizons Summit

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios